IntelGenx (TSXV:IGX; OTCQB:IGXT) reported that the peer-reviewed International Journal of Clinical Pharmacy published a study on montelukast’s effect on aging. IntelGenx is currently conducting a Phase...
Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...
Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...
SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...
SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...
LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...
Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...
H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...
Alliance Global Partners raised its price target for Heska (NASDAQ:HSKA) to $163.50 from $116.50 after hosting an investor webcast with the company’s CEO. The stock closed at $116.41 on Nov. 3. Analyst Ben Haynor writes...
LogicBio Therapeutics (NASDAQ:LOGC) appointed Mariana Nacht, Ph.D., as CSO, effective Nov. 30; and promoted Kyle Chiang, Ph.D., to the role of COO, effective Nov. 2. The company is expanding its leadership team to...
Aethlon Medical (NASDAQ:AEMD) appointed Charles Fisher, M.D., as CEO, effective Oct. 30. Dr. Fisher joined Aethlon as a member of its board and served as its chairman since November 2017. He succeeds Dr. Timothy Rodell...
Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the...